Eli Lilly & Co.: Takeaways from CSO Meetings

Research evidence excerpt

Eli Lilly & Co.: Takeaways from CSO Meetings

Idea

May 28, 2026 04:01 AM GMT

Morgan Stanley & Co. LLCMEli Lilly & Co. | North America Terence C Flynn, Ph.D.

Equity Analyst

Takeaways from CSO Meetings Terence.Flynn@morganstanley.comAlexander Yevdokimov, Ph.D. +1 212 761-2230

Research Associate

Alexander.Yevdokimov@morganstanley.com +1 212 761-2167

We recently hosted meetings with LLY's CSO where the Hailey Horowitz

discussion covered the company's pipeline (obesity/incretins, Research Associate

Hailey.Horowitz@morganstanley.com +1 212 761-5264

Alzheimer's, and cardiovascular, among other areas), perspective Chris Yu, J.D., Ph.D.

on AI for drug discovery/development, and recent business EquityChris.L.Yu@morganstanley.comAnalyst +1 212 761-2535

development activity. Connor M Massari

LLY’s goal is to have a very broad offering in the obesity space to serve patient Connor.Massari@morganstanley.com +1 212 761-2417

Damien H Kerner

needs. Mgmt noted that initial thoughts on market positioning/segmentation can Research Associate

sometimes be incorrect, until products are available in the market for physicians/ Damien.H.Kerner@morganstanley.com +1 212 761-3829

patients to try. Longer term LLY continues to expect orals (i.e., Foundayo) to Morgan Stanley India Company Private Limited+

represent a dominant piece of the overall market given convenience and cost. Saket Agarwal

Saket.Agarwal@morganstanley.com +91 22 6995-4012

Mgmt was very enthusiastic about Reta’s (GLP-GIP-glucagon) emerging profile

following the recent Ph3 obesity data (see our take HERE), which confirmed their Eli Lilly & Co. (LLY.N, LLY UN)

thesis for high BMI patients (i.e., 40+), but interestingly noted the drug could also Major Pharmaceuticals | United States of America